All Stories

  1. Long-Term Clinical Efficacy, Safety, and Polypharmacy Simplification of Levodopa–Entacapone–Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: An 18-Month Longitudinal Study
  2. Clinical Outcomes and Predictors of Response to Levodopa–Entacapone–Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: A Retrospective Cohort Study Over a 4-Year Period
  3. Distribution of NECAB1-Positive Neurons in Normal and Epileptic Brain—Expression Changes in Temporal Lobe Epilepsy and Modulation by Levetiracetam and Brivaracetam
  4. Antidiabetic GLP-1 Receptor Agonists Have Neuroprotective Properties in Experimental Animal Models of Alzheimer’s Disease
  5. Előrehaladott Parkinson-kóros betegek kezelése levodopa-entakapon-karbidopa intestinalis géllel: az első két év tapasztalata
  6. Levodopa–Entacapone–Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease: A Single Center Real-World Experience
  7. Starting with 24-h levodopa carbidopa intestinal gel at initiation in a large cohort of advanced Parkinson’s disease patients
  8. A Rare Case of Histopathologically Confirmed Creutzfeldt–Jakob Disease from Romania, Long Route to Diagnosis—Case Report and an Overview of the Romanian CJD Situation
  9. Az intestinalis gél bevezetésekor rögzített jellemzők tízéves változásai előrehaladott Parkinson-kóros betegekben
  10. Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: Observations and Dilemmas after 10 Years of Real-Life Experience
  11. Effect of continuing versus stopping pre-stroke antihypertensive agents within 12 h on outcome after stroke: A subgroup analysis of the efficacy of nitric oxide in stroke (ENOS) trial
  12. Management Challenges of Severe, Complex Dyskinesia. Data from a Large Cohort of Patients Treated with Levodopa-Carbidopa Intestinal Gel for Advanced Parkinson’s Disease
  13. Döntési szempontok és az eszközös terápia elfogadásához szükséges idő előrehaladott Parkinson-kórban
  14. Relationship between nitrate headache and outcome in patients with acute stroke: results from the efficacy of nitric oxide in stroke (ENOS) trial
  15. A gastrointestinalis panaszok felmérésének jelentősége előrehaladott Parkinson-kórban
  16. Levodopa-Carbidopa Intestinal Gel Infusion Therapy Discontinuation: A Ten-Year Retrospective Analysis of 204 Treated Patients
  17. Imaging markers of small vessel disease and brain frailty, and outcomes in acute stroke
  18. Profile Of Patients With Advanced Parkinson’s disease Suitable For Device-Aided Therapies: Restrospective Data Of A Large Cohort Of Romanian Patients
  19. Therapeutic strategies in the early stages of Parkinson’s disease: a cross-sectional evaluation of 15 years’ experience with a large cohort of Romanian patients
  20. Characteristics of levodopa treatment in advanced Parkinson’s disease
  21. It is safe to use transdermal glyceryl trinitrate to lower blood pressure in patients with acute ischaemic stroke with carotid stenosis
  22. Effect of Glyceryl Trinitrate on Hemodynamics in Acute Stroke
  23. DOPAMINE AGONISTS IN PARKINSON’S DISEASE THERAPY – 15 YEARS OF EXPERIENCE
  24. Central adjudication of serious adverse events did not affect trial’s safety results: Data from the Efficacy of Nitric Oxide in Stroke (ENOS) trial
  25. Selective monoamine oxidase B inhibitors for Parkinson's disease in Tirgu Mures, Romania
  26. Route of Feeding as a Proxy for Dysphagia After Stroke and the Effect of Transdermal Glyceryl Trinitrate: Data from the Efficacy of Nitric Oxide in Stroke Randomised Controlled Trial
  27. Diabetes, dementia, depresszió, distressz
  28. Continuing versus Stopping Prestroke Antihypertensive Therapy in Acute Intracerebral Hemorrhage: A Subgroup Analysis of the Efficacy of Nitric Oxide in Stroke Trial
  29. COMPARISON OF HOSPITALIZED ACUTE STROKE PATIENTS’ CHARACTERISTICS USING TWO LARGE CENTRAL-EASTERN EUROPEAN DATABASES
  30. Glyceryl Trinitrate for Acute Intracerebral Hemorrhage
  31. The role of ultrasound in the diagnosis of temporal arteritis
  32. Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial
  33. Baseline Characteristics of the 4011 Patients Recruited into the ‘Efficacy of Nitric Oxide in Stroke’ (ENOS) Trial
  34. Prestroke Alcohol Consumption and Smoking Are Not Associated with Stroke Severity, Disability at Discharge, and Case Fatality
  35. Common Carotid Artery Occlusion: A Case Series
  36. Procaine treatments for cognition and dementia — A Cochrane review
  37. Treatment of dementia and cognitive impairment: What can we learn from the Cochrane Library
  38. Procaine treatments for cognition and dementia
  39. Factors influencing hemorrhagic transformation in ischemic stroke: a clinicopathological comparison
  40. Mannitol Use in Acute Stroke
  41. Vinpocetine for cognitive impairment and dementia
  42. Subcortical features and cognitive performance in Hungarian cerebrovascular outpatients
  43. The Mures-Uzhgorod-Debrecen study: a comparison of hospital stroke services in Central-Eastern Europe
  44. Screening of vascular cognitive impairment on a Hungarian cohort